ATE392623T1 - METHOD FOR THE DIAGNOSIS OF SERIOUSLY ILL PATIENTS - Google Patents

METHOD FOR THE DIAGNOSIS OF SERIOUSLY ILL PATIENTS

Info

Publication number
ATE392623T1
ATE392623T1 AT04019308T AT04019308T ATE392623T1 AT E392623 T1 ATE392623 T1 AT E392623T1 AT 04019308 T AT04019308 T AT 04019308T AT 04019308 T AT04019308 T AT 04019308T AT E392623 T1 ATE392623 T1 AT E392623T1
Authority
AT
Austria
Prior art keywords
pro
ill patients
diagnosis
endothelin
adm
Prior art date
Application number
AT04019308T
Other languages
German (de)
Inventor
Andreas Bergmann
Joachim Struck
Nils G Morgenthaler
Original Assignee
Brahms Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brahms Ag filed Critical Brahms Ag
Application granted granted Critical
Publication of ATE392623T1 publication Critical patent/ATE392623T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]

Abstract

The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.
AT04019308T 2004-07-22 2004-08-13 METHOD FOR THE DIAGNOSIS OF SERIOUSLY ILL PATIENTS ATE392623T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017403 2004-07-22

Publications (1)

Publication Number Publication Date
ATE392623T1 true ATE392623T1 (en) 2008-05-15

Family

ID=34993078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04019308T ATE392623T1 (en) 2004-07-22 2004-08-13 METHOD FOR THE DIAGNOSIS OF SERIOUSLY ILL PATIENTS

Country Status (4)

Country Link
EP (1) EP1619505B1 (en)
AT (1) ATE392623T1 (en)
DE (1) DE602004013135T2 (en)
ES (1) ES2300681T3 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113529A2 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US8906857B2 (en) 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2550004T3 (en) 2006-04-04 2015-11-03 Singulex, Inc. High sensitivity system and troponin analysis methods
DE102006034142A1 (en) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides
DE102006052916A1 (en) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnosis and risk stratification of diabetes mellitus using MR-proADM
DE102006060835A1 (en) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnosis and risk stratification of acute coronary syndrome using CT-proET-1 in combination with NT-proBNP
DE102007021443A1 (en) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnosis and risk stratification using NT-proET-1
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
ES2431358T3 (en) * 2008-11-11 2013-11-26 B.R.A.H.M.S Gmbh Prognosis and risk assessment in patients suffering from heart failure by determining the concentration of ADM
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
RU2013102112A (en) * 2010-06-18 2014-07-27 Сезанн С.А.С. MARKERS FOR FORECASTING AND EVALUATING THE RISK OF DEVELOPMENT DUE TO PREGNANCY HYPERTENSION AND PREECLAMPSIA
CN103119446B (en) * 2010-06-18 2016-03-30 B.R.A.H.M.S有限公司 The biomarker that prediction cancer occurs
EP3497451A1 (en) * 2016-08-09 2019-06-19 B.R.A.H.M.S GmbH Histones and/or proadm as markers indicating an adverse event
WO2018216580A1 (en) * 2017-05-22 2018-11-29 東ソー株式会社 Method for providing prognostic prediction information on basis of adrenomedullin concentration fluctuation and reagent therefor
PL3682247T3 (en) * 2017-09-13 2022-04-25 B.R.A.H.M.S Gmbh Proadrenomedullin as a marker for abnormal platelet levels
EP3608673A1 (en) * 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613804B2 (en) * 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
DE19847690A1 (en) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments

Also Published As

Publication number Publication date
EP1619505B1 (en) 2008-04-16
DE602004013135T2 (en) 2009-07-02
EP1619505A3 (en) 2006-02-22
ES2300681T3 (en) 2008-06-16
DE602004013135D1 (en) 2008-05-29
EP1619505A2 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
ATE392623T1 (en) METHOD FOR THE DIAGNOSIS OF SERIOUSLY ILL PATIENTS
ATE554395T1 (en) DIAGNOSIS OF SEPTIC COMPLICATIONS
Moore et al. The role of veterinary team effectiveness in job satisfaction and burnout in companion animal veterinary clinics
Morgan et al. Mortality in levodopa-treated Parkinson's disease
EP2177908A3 (en) Diabetes-associated markers and methods of use thereof
ATE442592T1 (en) DETECTION AND/OR MONITORING OF SYNUCLEIN-ASSOCIATED DISEASES
WO2006086019A3 (en) Methods of treating diabetes
DE602005018264D1 (en) ARTIFICIAL BLOOD TANK
TW200600778A (en) An analyte measuring system which prevents the reuse of a test strip
DE60326214D1 (en) ASSAYS FOR THE MONITORING OF CANCER PATIENTS BASED ON THE MIRRORS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN SAMPLES FROM BODY FLUIDS
WO2004097429A3 (en) Apociii and the treatmentand diagnosis of diabetes
BRPI0511127A (en) prouroguaniline and synthetic analogues or proteolytically cleavage products derived therefrom as therapeutic and diagnostic agents for diseases involving salt and / or liquid homeostasis
ATE441107T1 (en) ASSAY FOR MONITORING CANCER PATIENTS BASED ON LEVELS OF THE EXTRACELLULAR DOMAIN (ECD) ANALYTE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN BODY FLUID SAMPLES
CY1122202T1 (en) DETERMINATION OF RISK FOR ANTIBIOTIC TREATMENT IN PATIENTS SUFFERING FROM A PRIMARY NON-INFECTIOUS DISEASE BY DETERMINATION OF THE PROCALCITONIN LEVEL
ATE354097T1 (en) METHOD FOR DIAGNOSIS OF LIVER FIBROSIS.
PL2057467T3 (en) Method for diagnosis of a disease involving an anti-at1-receptor antibody
ATE411771T1 (en) SELECTIVE EXPOSURE OF MINIATURE PROBE WITH INTEGRATED SENSOR ARRAYS FOR CONTINUOUS IN-VIVO DIAGNOSIS
MX2021015445A (en) Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (poc) diagnostic testing point-of-care (poc) measurement of absolute neutrophil function (anf).
NJ et al. Hemorrhoidal desarterialization guided by Doppler. A surgical alternative in hemorrhoidal disease management
Chudek et al. Coping with overweight strategies, self-esteem and body-esteem in the context of transactional analysis
AR051870A1 (en) METHODS FOR THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRITICAL DISEASE, AND THE USE OF ENDOTHELINE AND ENDOTHELINE AGONISTS WITH VASOCONSTRICTORY ACTIVITY IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PATIENTS WITH CRITICAL DISEASE
Zhuang et al. The posterolateral mid‐forearm perforator flap: Anatomical study and clinical application
Sudano et al. Secondary hypertension as a cause of treatment resistance
GB0409153D0 (en) Method of diagnosis
SE0200932D0 (en) Diagnosis marker

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1619505

Country of ref document: EP